Mendus Q4 2022: A clearer path forward - Redeye

Redeye comments on Mendus’ Q4 2022 report, with the company presenting a way forward for lead candidate vididencel (formerly DCP-001). Further, we believe the company will need to find a more sustainable financing solution than its current convertible debt arrangement with Negma Group. We adjust our model for the company’s new development plans and current resource constraints.

Länk till analysen i sin helhet: https://www.redeye.se/research/880504/mendus-q4-2022-a-clearer-path-forward?utm_source=finwire&utm_medium=RSS